Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Technology Licensing Office, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Clin Pharmacol Ther. 2016 Dec;100(6):647-653. doi: 10.1002/cpt.504. Epub 2016 Oct 22.
Despite the rapid pace of biomedical innovation, research and development (R&D) productivity in the pharmaceutical industry has not improved broadly. Increasingly, firms need to leverage new approaches to product development and commercial execution, while maintaining adaptability to rapid changes in the marketplace and in biomedical science. Firms are also seeking ways to capture some of the talent, infrastructure, and innovation that depends on federal R&D investment. As a result, a major transition to external innovation is taking place across the industry. One example of these external innovation initiatives is the Sanofi-MIT Partnership, which provided seed funding to MIT investigators to develop novel solutions and approaches in areas of interest to Sanofi. These projects were highly collaborative, with information and materials flowing both ways. The relatively small amount of funding and short time frame of the awards built an adaptable and flexible process to advance translational science.
尽管生物医学创新步伐迅速，但制药行业的研发（R&D）生产力并未广泛提高。越来越多的公司需要利用新产品开发和商业执行的新方法，同时保持对市场和生物医学科学快速变化的适应能力。公司还在寻求从联邦研发投资中获取一些人才、基础设施和创新的方法。因此，整个行业正在向外部创新进行重大转型。这些外部创新举措的一个例子是赛诺菲-麻省理工学院合作关系，该合作关系向麻省理工学院的研究人员提供种子资金，以开发赛诺菲感兴趣的领域的新解决方案和方法。这些项目是高度协作的，信息和材料双向流动。相对较少的资金和较短的奖励时间框架构建了一个适应性强、灵活的推进转化科学的过程。
